Tetrahydropyridoindole Derivatives as Estrogen Receptor Modulators for Cancer Treatment

ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)

Published March 25th, 2026

Detected April 2nd, 2026

Summary

European Patent Office published patent application EP4573092A1 by Olema Pharmaceuticals, Inc. for tetrahydropyridoindole derivatives as estrogen receptor modulators for cancer treatment. The application claims novel compounds and methods for treating cancer, with inventors including Brian R. Hearn, Rupa S. Shetty, David C. Myles, and Dirk A. Heerding. The patent is designated for all EU member states plus Switzerland, Norway, and other European countries.

View original document View source feed page

What changed

The EPO published patent application EP4573092A1 for tetrahydropyridoindole derivatives (C07D 471/04) as estrogen receptor modulators for cancer treatment (A61P 35/00, A61P 35/04). Filed by Olema Pharmaceuticals, Inc., the application claims novel compounds, pharmaceutical compositions containing them, and methods of treating cancer using these estrogen receptor modulators. The designated states cover all EU member states plus several European Economic Area countries.

Pharmaceutical companies developing breast cancer therapeutics or estrogen receptor-targeted compounds should review this patent landscape to identify potential freedom-to-operate concerns or licensing opportunities. Companies with competing cancer treatment technologies should assess whether their compounds fall within the scope of the claims. Patent counsel should monitor the prosecution of this application for claim scope and potential oppositions.

What to do next

Review patent claims to assess potential infringement risks for any estrogen receptor modulator cancer therapeutics in development
Consult with patent counsel regarding freedom-to-operate analysis if developing similar tetrahydropyridoindole compounds
Monitor patent prosecution for claim amendments that may expand or narrow the scope of protection

Source document (simplified)

← EPO Patent Bulletin

2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER

Publication EP4573092A1 Kind: A1 Mar 25, 2026

Applicants

Olema Pharmaceuticals, Inc.

Inventors

HEARN, Brian R., SHETTY, Rupa S., MYLES, David C., HEERDING, Dirk A.

IPC Classifications

C07D 471/04 20060101AFI20240223BHEP A61K 31/437 20060101ALI20240223BHEP A61P 35/00 20060101ALI20240223BHEP A61P 35/04 20060101ALI20240223BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →